blood

Catalan Health Department expects to exceed last year's participation in week-long campaign starting Friday 11

Catalan Health Department expects 8,000 people to take part in one week

Every day in every hospital in the world blood is needed. The only way to get it is from donations, since blood cannot be created artificially. Each altruist action may serve to help three different patients. In Catalonia, for the system to work optimally 1,000 donations a day would be needed but the average donation figure is lower. Everyone can donate if they weigh over 50kg, since a donation is 450ml of blood and a minimum weight is required. Men can do it four times a year and women three times. There are now various mobile units that travel throughout Catalonia to make donating more accessible to donors.

During the first half of the year, the revenues of the Catalan multinational pharmaceutical company Grifols rose by 16.7% to €1.61 bilion, 75% of which came from the Bioscience division and 18% from Diagnostic. Compared to the first quarter, the proportion of total sales generated by each of the group’s divisions remains unchanged after the acquisition of Novartis' diagnostic business. The world´s third-largest blood-derivate product maker, Grifols obtained a net profit of €224.8 million, 23% more compared with the same period last year, as reported by the company to the Spanish Stock Exchange Authority (CNMV). These positive figures were achieved due to the maintenance of financial costs, made possible by improved financial conditions, despite having increased debt in absolute terms.

A plasma fractionation plant installed in Clayton, North Carolina by the company Grífols was unveiled on Tuesday by the President of the Catalan Government, Artur Mas, along with the President and CEO of the pharmaceutical, Víctor Grífols, and the State Governor, Pat McCrory. The new plant is 14,400 square metres big, will create over 200 jobs and represents an investment of 260 million euros. Expected to be operational by 2015, it will the largest and one of the most advanced plasma fractionation plants in the world. Grífols already has 2,300 employees in the state of North Carolina and it is among the world's top pharmaceuticals within the blood-derivates market. A few weeks ago, Víctor Grífols gave his support to the Catalan President and the self-determination process, which he confirmed on Tuesday.

The profits of Catalan pharmaceutical company Grífols in 2013 grew by 34.6% over the previous year, reaching €345.6 million, as reported by the multinational to the Spanish Stock Exchange Regulation Authority (CNMV). The turnover of the company, based in Greater Barcelona, amounted to €2.75 billion, representing a 4.6% increase on 2012 figures. The geographical expansion of the pharmaceutical company has helped mitigating the effects of volatility in currencies, especially between the euro and the dollar. The Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) grew by 9.6% compared to 2012 and stood at €864.6 million, driven by an increase in the sales of plasma proteins and the optimization of the expenses for raw materials and manufacturing.

The Catalan pharmaceutical company Grifols, the third world leader in the production of blood plasma based technologies, has seen its turnover increase by 15% in the first half of 2012 to €1.32 billion. Its net profit for the first half of 2012 was €133.5 million, seven times that of the previous year. The company’s success is attributed to its wide geographical consumer base and the recent purchase of US based Talecris Plasma Resources.

The Catalan pharmaceutical company Grífols, third worldwide company in plasma derivatives, has signed a cooperation agreement with the Shanghai Blood Bank. The agreement, which strengthens the presence of the Catalan company in China, promotes blood genotyping research. The Chinese institution will use the Grifols’ genetic test BLOODchip in transfusion compatibility studies. Shanghai Blood Bank serves over 20 million people and receives more than 300.000 donations per year. In 2011, Grifols sales in China grew by 30%.

The Federation of Blood Donors in Catalonia wants to reach the young population and to raise the number of donations. Besides, the Catalan pharmaceutical company Grifols asked for a change in the law in order to pay for giving blood. This measure would be an incentive to increase the stock of plasma.

Barcelona’s Hospital Clínic has coordinated a world pioneer medical study with 60,000 patients. The study has compared the effectiveness of early detection of colon cancer by using a colonoscopy or a specific analysis searching blood in the patients’ faeces. The findings have proven that both diagnostic tests are equally reliable. Considering the differences between the financial costs of both tests, health risks, and comfort, colonoscopy might only be used for confirmation or treatment purposes. In addition, from now on all people older than 50 might be regularly checked in an easier and cheaper manner.

The Catalan pharmaceutical and chemical company was identified in a Wikileaks cable from the U.S. State Department as one of three strategic items the United States had in Spain, together with the natural gas pipeline from Algeria and the Gibraltar Strait. Grifols leads the blood plasma-based products’ market in Europe and is expanding its U.S. presence.